Biologic Therapies for Autoimmune and Connective Tissue Diseases

Immunology and Allergy Clinics of North America

Volumn 37, Issue 2, 2017, Pages 283-299

  Wolfe, Rachel M ^a   Ang, Dennis C ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Ankylosing spondylitis; Biologic therapy; Gout; Lupus; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

ABATACEPT; ADALIMUMAB; BELIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PLACEBO; RITUXIMAB; SECUKINUMAB; TOCILIZUMAB; TOFACITINIB; USTEKINUMAB; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS; AUTOIMMUNE DISEASE; BIOLOGICAL THERAPY; CLINICAL EFFECTIVENESS; CONNECTIVE TISSUE DISEASE; DRUG APPROVAL; DRUG EFFICACY; DRUG MONITORING; FOOD AND DRUG ADMINISTRATION; HUMAN; LOADING DRUG DOSE; MONOTHERAPY; MYOSITIS; OUTCOME ASSESSMENT; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT INDICATION; VASCULITIS; GOUT; IMMUNOLOGY; PROCEDURES; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; AUTOIMMUNE DISEASES; BIOLOGICAL PRODUCTS; BIOLOGICAL THERAPY; CONNECTIVE TISSUE DISEASES; GOUT; HUMANS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; VASCULITIS;

EID: 85014126009     PISSN: 08898561     EISSN: 15578607     Source Type: Journal    
DOI: 10.1016/j.iac.2017.01.005     Document Type: Review

References (78)

1. 1 Choy, E.H.S., Panayi, G.S., Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 344 (2001), 907–916.
2. 2 Felson, D.T., Anderson, J.J., Boers, M., et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 38:6 (1995), 727–735.
3. 3 Fransen, J., Creemers, M.C.W., Van Riel, P.L., Remission in rheumatoid arthritis: agreement of the Disease Active Score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 43:1 (2004), 1252–1255.
4. 4 Fransen, J., Antoni, C., Mease, P.J., Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomized controlled trials of two tumour necrosis factor inhibitors. Ann Rheum Dis 65:10 (2006), 1373–1378.
5. 5 Chen, Y.F., Jobanputra, P., Barton, P., A systemic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 10:42 (2006), iii–iv xi-xiii, 1–229.
6. 6 Caporali, R., Pallavicini, R.B., Filippini, M., et al. Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. Autoimmun Rev 8 (2009), 274–280.
7. 7 Caporali, R., Sarzi-Puttini, P., Atzeni, F., et al. Switching TNF-alpha antagonist in rheumatoid arthritis: the experience of the Lorhen registry. Autoimmun Rev 9:6 (2010), 465–469.
8. 8 Ma, X., Xu, S., TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep 1:2 (2013), 177–184.
9. 9 Santos-Moreno, P., Sanchez, G., Gomez, D., et al. Direct comparative effectiveness among 3 anti-tumor necrosis factor biologics in a real-life cohort of patients with rheumatoid arthritis. J Clin Rheumatol 22:2 (2016), 57–62.
10. 10 Greenberg, J.D., Reed, G., Decktor, D., et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis 71 (2012), 1134–1142.
11. 11 Aaltonen, K.J., Virkki, L.M., Malmivaara, A., et al. Systemic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS One, 7(1), 2012, e30275.
12. 12 Maini, R.N., Taylor, P.C., Szechinski, J., et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 54:9 (2006), 2817–2829.
13. 13 Emery, P., Keystone, E., Tony, H.P., et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67:11 (2008), 1516–1523.
14. 14 Navarro, G., Taroumian, S., Barroso, N., Tocilizumab in rheumatoid arthritis: a meta-analysis of efficacy and selected clinical conundrums. Semin Arthritis Rheum 43 (2014), 458–469.
15. 15 Genovese, M.C., McKay, J.D., Nasonov, E.L., et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the Tocilizumab in Combination with Traditional Disease-modifying Antirheumatic Drug Therapy study. Arthritis Rheum 58:10 (2008), 2968–2980.
16. 16 Gabay, C., Emery, P., van Vollenhoven, R., et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet 381 (2013), 1541–1550.
17. 17 Burmester, G.R., Rubbert-Roth, A., Cantagrel, A., et al. A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann Rheum Dis 73:1 (2014), 69–74.
18. 18 Ogata, A., Tanimura, K., Sugimoto, T., et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66:3 (2014), 344–354.
19. 19 Kivitz, A., Olech, E., Borofsky, M., et al. Subcutaneous tocilizumab versus placebo in combination with disease-modifying antirheumatic drugs in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66:11 (2014), 1653–1661.
20. 20 Ogata, A., Atsumi, T.A., Fukuda, T., et al. Sustainable efficacy of switching from intravenous to subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res 67:10 (2015), 1354–1362.
21. 21 Schiff, M., Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology 52 (2013), 986–997.
22. 22 Genovese, M.C., Tena, C.P., Covarrubias, A., et al. Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial. J Rheumatol 44:4 (2014), 629–639.
23. 23 Schiff, M., Weinblatt, M.E., Valente, R., Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial. Ann Rheum Dis 73 (2014), 86–94.
24. 24 Nash, P., Nayiager, S., Genovese, M., et al. Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel-Arm, Open-Label Study. Arthritis Care Res (Hoboken) 65:5 (2013), 718–728.
25. 25 Cohen, S.B., Emery, P., Greenwald, M.W., et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54 (2006), 2793–2806.
26. 26 Keystone, E.C., Cohen, S.B., Emery, P., et al. Multiple courses of rituximab produce sustained clinical and radiographic efficacy and safety in patients with rheumatoid arthritis and an inadequate response to 1 or more tumor necrosis factor inhibitors: 5 year data from the REFLEX study. J Rheumatol 39:12 (2012), 2238–2246.
27. 27 Tak, P.P., Rigby, W.F., Rubbert-Roth, A., et al. Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis 70:1 (2011), 39–46.
28. 28 Emery, P., Deodhar, A., Rigby, W.F., et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 69:9 (2010), 1629–1635.
29. 29 Emery, P., Fleischmann, R., Filipowicz-Sosnowska, A., et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:5 (2006), 1390–1400.
30. 30 Rubbert-Roth, A., Tak, P.P., Zerbini, C., Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a phase III randomized study (MIRROR). Rheumatology (Oxford) 49:9 (2010), 1683–1693.
31. 31 Chatzidionysiou, K., Lie, E., Nasonov, E., et al. Effectiveness of two different doses of rituximab for the treatment of rheumatoid arthritis in an international cohort: data from the CERERRA collaboration. Arthritis Res Ther, 18, 2016, 50.
32. 32 Song, G.G., Bae, S.C., Lee, Y.H., Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials. Korean J Intern Med 29 (2014), 656–663.
33. 33 Charles-Schoeman, C., Burmester, G., Nash, P., et al. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic disease-modifying antirheumatic drugs. Ann Rheum Dis 75:7 (2016), 1293–1301.
34. 34 Navarra, S.V., Guzman, R.M., Gallacher, A.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematous: a randomized, placebo-controlled, phase 3 trial. Lancet 377 (2011), 721–731.
35. 35 Furie, R., Petri, M., Zamani, O., A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B-lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 63:12 (2011), 3918–3930.
36. 36 Manzi, S., Sánchez-Guerrero, J., Merrill, J.T., et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 71:11 (2012), 1833–1888.
37. 37 van Vollenhoven, R.F., Petri, M.A., Crevera, R., et al. Belimumab in the treatment of systemic lupus erythematous: high disease activity predictors of response. Ann Rheum Dis 71:8 (2012), 1343–1349.
38. 38 Rovin, B.H., Furie, R., Latinis, K., et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 64:4 (2012), 1215–1226.
39. 39 Merrill, J.T., Neuwelt, C.M., Wallace, D.J., et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus: the randomized double-blind phase II/III Systemic Lupus Erythematosus Evaluation of Rituximab trial. Arthritis Rheum 62:1 (2010), 222–233.
40. 40 Murray, E., Perry, M., Off-label use of rituximab in systemic lupus erythematosus: a systemic review. Clin Rheumatol 29 (2010), 707–716.
41. 41 Cobo-Ibanez, T., Loza-Santamaria, E., Pego-Reigosa, J.M., et al. Efficacy and safety of rituximab in the treatment of non-renal systemic lupus erythematous: a systemic review. Semin Arthritis Rheum 44 (2014), 175–185.
42. 42 Lobo Borba, H.H., Funke, A., Wiens, A., Update on biological therapy for systemic lupus erythematosus. Curr Rheumatol Rep, 18, 2016, 44.
43. 43 Askanase, A., Byron, M., Keyes-Elstein, L., et al. Treatment of lupus nephritis with abatacept and cyclophosphamide efficacy and safety study. Arthritis Rheum 66:11 (2014), 3096–3104.
44. 44 Wofsy, D., Hillson, J.L., Diamond, B., Abatacept for lupus nephritis: alternative definitions of complete remission support conflicting conclusions. Arthritis Rheum 64:11 (2012), 3660–3665.
45. 45 Merrill, J.T., Burgos-Vargas, R., Westhovens, R., et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematous. Arthritis Rheum 62:10 (2010), 3077–3087.
46. 46 Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis. Available at: https://clinicaltrials.gov/ct2/show/NCT01714817. Accessed June 29, 2016.
47. 47 Fasano, S., Gordon, P., Hajji, R., et al. Rituximab in treatment of inflammatory myopathies: a review. Rheumatology (Oxford) 55:7 (2016), 1318–1324.
48. 48 Oddis, C.V., Reed, A.M., Aggarawal, R., et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and polymyositis: a randomized, placebo-phase trial. Arthritis Rheum 65:2 (2013), 314–324.
49. 49 Aggarwal, R., Bandos, A., Reed, A.M., et al. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis. Arthritis Rheum 66 (2014), 740–749.
50. 50 The Muscle Study Group, A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol 70:3 (2011), 427–436.
51. 51 Brunasso, A.M.G., Aberer, W., Massone, C., New onset of dermatomyositis/polymyositis during anti-TNF-α therapies: a systematic literature review. ScientificWorldJournal, 2014, 2014, 179180.
52. 52 George Washington University, Abatacept for the treatment of refractory juvenile dermatomyositis. In: ClinicalTrials.gov [Internet]. 2000, National Library of Medicine (US), Bethesda (MD) Available at: https://clinicaltrials.gov/ct2/show/NCT02043548 Accessed Jun 28, 2016. NLM Identifier: NCT02043548.
53. 53 Moghadam-Kia, S., Oddis, C.V., Aggarawal, R., Modern therapies for idiopathic inflammatory myopathies: role of biologics. Clin Rev Allergy Immunol 52:1 (2017), 81–87.
54. 54 University of Pittsburgh, Tocilizumab in the treatment of refractory polymyositis and dermatomyositis. In: ClinicalTrials.gov [Internet]. 2000, National Library of Medicine (US), Bethesda (MD) Available at: https://clinicaltrials.gov/ct2/show/NCT02594735 Accessed Jun 28, 2016. NLM Identifier: NCT02594735.
55. 55 Garrett, S., Jenkinson, T., Kennedy, L.G., A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:12 (1994), 2286–2291.
56. 56 Anderson, J.J., Baron, G., van der Heijde, D., Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 44:8 (2001), 1876–1886.
57. 57 Maxwell, L.J., Zochling, J., Boonen, A., et al. TNF-alpha inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev(4), 2015 CD005468.
58. 58 Callhoff, J., Sieper, J., Weiß, A., et al. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis 74 (2015), 1241–1248.
59. 59 Maneiro, J.R., Souto, A., Salgado, E., et al. Predictors of response to TNF antagonists in patients with ankylosing spondylitis and psoriatic arthritis: systemic review and meta-analysis. RMD Open, 1(1), 2015, e000017.
60. 60 Baeten, D., Sieper, J., Braun, J., et al. Secukinumab, an IL-17A inhibitor in ankylosing spondylitis. N Engl J Med 373:26 (2015), 2534–2548.
61. 61 Saad, A.A., Symmons, D.P.M., Noyce, P.R., et al. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systemic review and metaanalysis of randomized control trials. J Rheumatol 35 (2008), 883–890.
62. 62 Lubrano, E., Parson, W.J., Perrotta, F.M., Assessment of response to treatment, remission and minimal disease activity in axial psoriatic arthritis treated with tumor necrosis factor inhibitors. J Rheumatol 43 (2016), 918–923.
63. 63 McInnes, I.B., Kavanaugh, A., Gottlieb, A.B., et al., on behalf of the PSUMMIT 1 Study Group. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicenter, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 382 (2013), 780–789.
64. 64 Richlin, C., Rahman, P., Kavanaugh, A., et al., on behalf of the PSUMIIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological anti-tumor necrosis factor therapy: 6-month and 1 year results of the phase 3, multicentre, double-blinded, placebo-controlled, randomized PSUMMIT 2 trial. Ann Rheum Dis 73 (2014), 990–999.
65. 65 Strand, V., Mease, P., Gossec, L., Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomized phase III trial (FUTURE 1). Ann Rheum Dis 76:1 (2017), 203–207.
66. 66 McInnes, I.B., Mease, P.J., Kirkham, B., et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomized, double-blind, placebo-controlled, phase 3 trial. Lancet 386 (2015), 1137–1146.
67. 67 Stone, J.H., Merkel, P.A., Spiera, R., et al. Rituximab versus cyclophosphamide in ANCA-associated vasculitis. N Engl J Med 363 (2010), 221–232.
68. 68 Jones, R.B., Tervaert, J.W., Hauser, T., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis. N Engl J Med 363 (2010), 211–220.
69. 69 Jones, R.B., Furuta, S., Tervaert, J.W., et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2 year results of randomized trial. Ann Rheum Dis 74 (2015), 1178–1182.
70. 70 Guillevin, L., Pagnouz, C., Karra, S., et al. Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med 371 (2014), 1771–1780.
71. 71 Osman, M., Pagnoux, C., Dryden, D.M., et al. The role of biological agents in the management of large vessel vasculitis (LVV): a systemic review and meta-analysis. PLoS One, 9(12), 2014, e115026.
72. 72 Regent, A., Redeker, S., Deroux, A., et al. Tocilizumab in giant cell arteritis: a multicenter retrospective study of 34 patients. J Rheumatol 43:8 (2016), 1547–1552.
73. 73 Tuckwell, K., Collinson, N., Klearman, M., et al. Baseline data on patients enrolled in a randomized, double-blind trial of tocilizumab in giant cell arteritis [abstract]. Arthritis Rheumatol, 67(Suppl 10), 2015 Available at: http://acrabstracts.org/abstract/baseline-data-on-patients-enrolled-in-a-randomized-double-blind-trial-of-tocilizumab-in-giant-cell-arteritis/. Accessed June 29, 2016.
74. 74 So, A., Smedt, D.E., Revaz, S., et al. A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res, 9(2), 2007, R28.
75. 75 Schlesinger, N., Anti-interleukin-1 therapy in the management of gout. Curr Rheumatol Rep, 16, 2014, 398.
76. 76 Schlesinger, N., De Meulemeester, M., Pikhlak, A., et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 71:11 (2012), 1839–1848.
77. 77 Eli Lily and Company, A randomized, double-blind, placebo-controlled, phase 3 study evaluating the efficacy and safety of baricitinib in patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to methotrexate therapy. In: ClinicalTrials.gov [Internet]. 2000, National Library of Medicine (US), Bethesda (MD) Available at: https://clinicaltrials.gov/ct2/show/NCT02265705 Accessed Jun 28, 2016. Identifier: NCT02265705.
78. 78 FDA approved drug products. US Food and Drug Administration Web site. Available at: https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Search_Drug_Name Last updated: daily. Accessed June 15, 2016.